Related Experiment Videos
Epigenetic targets for immune intervention in human malignancies
Michele Maio1, Sandra Coral, Elisabetta Fratta
1Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano 33081, Italy. mmaio@cro.it
Oncogene
|October 7, 2003
Summary
Epigenetic changes in cancer can suppress immune recognition. Epigenetic drugs can restore this recognition, offering new avenues for combined cancer therapy.
Area of Science:
- Oncology
- Immunology
- Epigenetics
Background:
- Epigenetic alterations, including DNA methylation and histone acetylation, are implicated in cancer development.
- These epigenetic changes can reduce the cancer cells' ability to be recognized by the immune system.
Purpose of the Study:
- To explore how epigenetic modifications affect cancer cell immunogenicity.
- To investigate the potential of epigenetic drugs in restoring anti-tumor immunity.
Main Methods:
- Review of emerging evidence on epigenetic events in cancer.
- Analysis of the impact of DNA methylation and histone deacetylation on tumor recognition complex components.
- Evaluation of pharmacologic agents targeting epigenetic modifications.
Main Results:
- Deregulated DNA methylation and histone acetylation impair cancer cell immunogenicity by downregulating key components of the tumor recognition complex.
- Pharmacologic agents that modify DNA methylation and histone acetylation can restore the expression of these components.
- Restored expression enhances cancer cell immunogenicity and immune recognition.
Conclusions:
- Epigenetic drugs can reverse immunosuppressive epigenetic changes in cancer cells.
- These drugs hold promise for developing novel chemoimmunotherapeutic strategies against cancer.